Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067636) PROTEIN EXPRESSION ANALYSIS FOR BREAST CANCER PROGNOSIS AND TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067636 International Application No.: PCT/US2018/052981
Publication Date: 04.04.2019 International Filing Date: 26.09.2018
IPC:
G01N 33/574 (2006.01) ,G01N 33/68 (2006.01) ,C07D 311/78 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
311
Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02
ortho- or peri-condensed with carbocyclic rings or ring systems
78
Ring systems having three or more relevant rings
Applicants:
NANTOMICS, LLC [US/US]; 9920 Jefferson Boulevard Culver City, CA 90232, US
Inventors:
SCHWARTZ, Sarit; US
CECCHI, Fabiola; US
TIAN, Yuan; US
YAU, Christina; US
SZETO, Christopher; US
HEMBROUGH, Todd; US
BENZ, Stephen Charles; US
Agent:
RAKERS, Leanne M.; US
Priority Data:
62/563,51326.09.2017US
62/595,55306.12.2017US
Title (EN) PROTEIN EXPRESSION ANALYSIS FOR BREAST CANCER PROGNOSIS AND TREATMENT
(FR) ANALYSE DE L'EXPRESSION PROTÉIQUE POUR LE PRONOSTIC ET LE TRAITEMENT DU CANCER DU SEIN
Abstract:
(EN) Methods are provided for identifying whether a cancer patient, and especially a breast cancer patient, will be responsive to treatment. Specified TOPO2A, IDO1 and/or p16 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in cancer cells collected from tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the cancer patient will positively respond to treatment. Measurement of TOPO2A provides a direct indication of whether a patient will respond to anthracycline-containing therapy, and, in particular, neoadjuvant anthracycline-containing therapy. Quantitative levels of IDO1 and p16 are compared to reference levels in order to determine if a breast cancer patient will likely demonstrate a pathologically complete response (pCR) of cancer after cancer therapy treatment, irrespective of the chosen treatment.
(FR) L'invention concerne des méthodes pour déterminer si un patient atteint de cancer, et en particulier une patiente atteinte d'un cancer du sein, répondra au traitement. Des fragments peptidiques spécifiés de TOPO2A, IDO1 et/ou p16 sont détectés et quantifiés avec précision par SRM-spectrométrie de masse directement dans des cellules cancéreuses collectées à partir d'un tissu tumoral prélevé sur une patiente atteinte de cancer, puis comparés à des niveaux de référence pour déterminer si la patiente atteinte de cancer réagira positivement au traitement. La mesure de TOPO2A fournit une indication directe sur le fait qu'une patiente répondra ou non à une thérapie contenant de l'anthracycline, et, en particulier, à une thérapie contenant une anthracycline à titre de néoadjuvant. Les niveaux quantitatifs de IDO1 et p16 sont comparés à des niveaux de référence pour déterminer si une patiente atteinte d'un cancer du sein sera susceptible de manifester une réponse pathologiquement complète (pCR) du cancer après un traitement de thérapie contre le cancer, indépendamment du traitement choisi.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)